Amgen (AMGN) Change in Accured Expenses (2009 - 2026)

Amgen's Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$75.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 3.85% year-over-year to -$75.0 million; the TTM figure through Mar 2026 stood at -$153.0 million (down 318.57% YoY), while the FY2025 annual figure was -$156.0 million, down 269.57% from the prior year.
• Change in Accured Expenses was -$75.0 million for Q1 2026 at Amgen, down from $94.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.1 billion in Q4 2023 to a low of -$501.0 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $53.6 million across 5 years, with a median of -$75.0 million in 2026.
• Biggest YoY gain for Change in Accured Expenses was 401.37% in 2023; the steepest drop was 219.57% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$366.0 million in 2022, then jumped by 401.37% to $1.1 billion in 2023, then plunged by 34.0% to $728.0 million in 2024, then sank by 87.09% to $94.0 million in 2025, then tumbled by 179.79% to -$75.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$75.0 million (Q1 2026), $94.0 million (Q4 2025), and -$180.0 million (Q3 2025), per Business Quant data.